Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study.

Abstract

BACKGROUND:

We sought to evaluate prognostic factors affecting overall survival (OS), and to investigate the role of palliative chemotherapy using propensity score-based weighting, in patients with advanced small bowel adenocarcinoma (SBA).

METHODS:

Data from a total of 91 patients diagnosed with advanced SBA at the Asan Medical Center between January 1989 and December 2009 were retrospectively analyzed. Patients were split into two groups, those who did and did not receive palliative chemotherapy.

RESULTS:

Overall, 81 patients (89.0%) died, at a median survival time of 6.6 months (95% confidence interval [CI], 5.5 - 7.5 months). The 40 patients receiving chemotherapy showed overall response and disease control rates of 11.1% and 37.0%, respectively, with OS and progression-free survival (PFS) of 11.8 months (95% CI, 4.6 - 19.0 months) and 5.7 months (95% CI, 3.5 - 8.0 months), respectively. The 41 patients who did not receive chemotherapy had an OS of 4.1 months (95% CI, 3.1 - 5.1 months) and a PFS of 1.3 months (95% CI, 0.8 - 1.7 months). Multivariate analysis showed that lack of tumor resection, non-prescription of chemotherapy, liver metastasis, and intra-abdominal lymph node metastasis, were all independently associated with poor survival outcomes. After inverse probability of treatment weighting (IPTW) adjustment, the group that did not receive chemotherapy was at a significantly higher risk of mortality (HR 3.44, 95% CI 2.03 - 5.83, p < 0.001) than were patients receiving chemotherapy.

CONCLUSION:

Palliative chemotherapy may improve survival outcomes in patients with advanced SBA.

• Authors: Dong Hoe Koo, Sung-Cheol Yun, Yong Sang Hong, Min-Hee Ryu, Jae-Lyun Lee, Heung-Moon Chang, Baek-Yeol Ryoo, Yoon-Koo Kang, Tae Won Kim
• Journal: BMC cancer (BMC Cancer) Vol. 11 Pg. 205 (May 27 2011) ISSN: 1471-2407 [Electronic] England
• PMID: 21619586 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents

Topics

• Adenocarcinoma (diagnosis, drug therapy, mortality, pathology)
• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Agents (therapeutic use)
• Factor Analysis, Statistical
• Humans
• Intestine, Small (pathology)
• Middle Aged
• Prognosis
• Retrospective Studies
• Survival Analysis
• Treatment Outcome